Introducing ZIRABEV

ZIRABEV is a biosimilar* to Avastin® (bevacizumab) that was approved by the FDA based on the totality of evidence1,2
ZIRABEV offers the potential to help address treatment costs and shows no clinically meaningful differences to Avastin1-3

Clinical Information